(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁷: C12N

(21) International Application Number: PCT/US02/11694

(22) International Filing Date: 12 April 2002 (12.04.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/283,837   13 April 2001 (13.04.2001)   US
60/298,811   15 June 2001 (15.06.2001)   US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:
US   60/283,837 (CON)
Filed on   13 April 2001 (13.04.2001)
US   60/298,811 (CON)
Filed on   15 June 2001 (15.06.2001)

(71) Applicant *(for all designated States except US)*: **AN-TEROGEN CO., LTD.** [KR/KR]; 399-1 Daebang-dong, Dongjak-gu, Seoul 156-811 (KR).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **LEE, Ike, W.** [US/US]; 178 Edgehill Road, Norwood, MA 02062 (US). **LIU, Guizhen** [CN/US]; 102 Village Road, West, Norwood, MA 02062 (US). **HAMPE, James** [US/US];

107 Gainsville Road, Dedham, MA 02026 (US). **CROIS-SANT, Jeffrey, D.** [US/US]; 12 Seagull Lane, Scituate, MA 02066 (US).

(74) Agent: BIEKER-BRADY, Kristina; Clark & Elbing LLP, 101 Federal Street, Boston, MA 02110 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS AND REAGENTS FOR CELL TRANSPLANTATION

(57) Abstract: The invention features methods for producing cells for transplantation into myocardial tissue of a mammal (e.g., a human). The method includes the steps of (a) providing a population of bone marrow stem cells; (b) culturing the cells under conditions that induce the cells to become cardiomyogenic cells; (c) monitoring the state of differentiation of the cells of step (b); and (d) collecting the cells of step (b) when at least about 10% and as many as 100% of the cells are cardiomyogenic cells. The bone marrow stem cells can be, for example, human bone marrow stem cells. In one embodiment, the method includes the step of transplanting the differentiated stem cells into a mammal (e.g., a human).

5   **METHODS AND REAGENTS FOR CELL TRANSPLANTATION**

Background of the Invention

The invention relates to the field of cell transplantation.

The possibility of bone marrow being an *in vivo* source of circulating

10   cardiomyocyte progenitors has been suggested. In one experiment, transplanted

bone marrow-derived cells were observed to be distributed in a dystrophic mouse

heart. Although the molecular characteristics of these cells were not identified,

their location in the heart tissue indicated these cells were cardiomyocytes. The

ability of bone marrow mesenchymal stem cells (BMSCs) to differentiate as

15   beating cardiomyocytes following introduction of inductive agents such as 5-

azacytidine has also been shown. Based on these findings, BMSCs have been

proposed to be a source of cells for treatment of cardiac disease and cardiac

abnormalities.

Despite the potential therapeutic value of BMSCs, current cell

20   transplantation methods for cardiac tissue are clinically inadequate because rate

of implant incorporation into the host tissue is poor. For example, Orlic *et al.*

(Nature 410: 701-705, 2001) reported that only 40% of mice receiving BMSC

transplants showed some myocardial repair.

Thus, there is a need for cell transplantation methods having high rates of

25   cell incorporation and cell survival.

Summary of the Invention

We have discovered a method by which the induction of the differentiation

of stem cells can be monitored *in vitro* and the stem cells then collected for

30   transplantation.

Accordingly, the invention features a method for producing cells for transplantation into myocardial tissue of a mammal (e.g., a human). The method includes the steps of (a) providing a population of stem cells that have not been immortalized; (b) culturing the cells under conditions that induce the cells to

5   become cardiomyogenic cells (e.g., cardiomyocyte progenitor cells); (c) monitoring the state of differentiation of the cells of step (b); and (d) collecting the cells of step (b) when at least about 10% and as many as about 100%, of the collected cells are cardiomyogenic cells. The cells can be, for example, human, pig, or baboon BMSCs. In one embodiment, the method further includes the step

10   of (e) transplanting the cells of step (d) into a mammal (e.g., a human). The transplantation can be an autologous transplantation, i.e., cells from the mammal to be treated are transplanted. Desirably, at least about 15%, 20%, 30%, 40%, or 50% of the cells collected are cardiomyogenic cells (e.g., cardiomyocyte progenitor cells). Desirably, as many as about 60%, 70%, 80%, 90%, 95%, or

15   99% of the cells collected are cardiomyogenic cells. Most desirably, the cells are collected when at least about 50% and as many as about 80%, of the collected cells are cardiomyogenic cells.

We have also discovered a therapeutic cellular transplantation method in which blood vessels and myocardial tissue are collectively regenerated in the area

20   of treated myocardium.

Following myocardial infarction, reduction of blood supply to the affected area compromises the health of endogenous cardiomyocytes. In order to increase the viability of injected cells, it is desirable that the host mammal develops a network of blood vessels to supply oxygen and nutrients required for cellular

25   survival.

Based on the observation that coronary vasculature in the myocardium is formed from endothelial and vascular smooth muscle progenitor cells migrating from the epicardium into the myocardium, we believe that administration of endothelial and vascular smooth muscle progenitor cell types in conjunction with

30   cardiomyocytes or cardiomyocyte progenitors will facilitate the formation of the vascular network required for therapeutically significant cardiomyocyte survival.

Infarcted myocardium is repaired by regenerating new cardiac muscle cells in concert with new blood vessels using combinations of cardiomyocyte progenitor cells, endothelial progenitor cells, and vascular smooth muscle progenitor cells. In one example, the progenitor cells are derived *ex vivo* from stem cells.

5   Accordingly, in a second aspect, the invention also features a method for producing cells primed to differentiate as endothelial cells for transplantation into myocardial tissue of a mammal (e.g., a human). The method includes the steps of (a) providing a population of stem cells that have not been immortalized; (b) culturing the cells under conditions that induce the cells to become endothelial

10   cells; and (c) collecting the cells of step (b) when at least about 10% and as many as 100% of the cells are endothelial progenitor cells.

In a third aspect, the invention also features a method for producing cells primed to differentiate as vascular smooth muscle cells for transplantation into myocardial tissue of a mammal (e.g., a human). The method includes the steps of

15   (a) providing a population of stem cells that have not been immortalized; (b) culturing the cells under conditions that induce the cells to become vascular smooth muscle cells; and (c) collecting the cells of step (b) when at least about 10% and as many as about 100% of the cells are vascular smooth muscle progenitor cells.

20   In a fourth aspect, the invention features a method for treating a mammal (e.g., a human) diagnosed as having a disorder characterized by insufficient cardiac function. This method includes the steps of introducing to the myocardial tissue of the mammal the following three types of cells: (1) cardiomyocytes or cardiomyocyte progenitor cells; (2) endothelial cells or endothelial cell

25   progenitors; and (3) vascular smooth muscle cells or vascular smooth muscle cell progenitors in amounts sufficient to improve cardiac function. In one example, for each injection, one million cardiomyocyte progenitor cells are injected into myocardium with the other two cell types in a ratio of about 10:1:1 (cardiomyocyte progenitors:endothelial cell progenitors:smooth muscle cell

30   progenitors). Other ratios can also be used. For example, the ratio of cardiomyocyte progenitors to endothelial cell progenitors or vascular smooth

muscle cell progenitors can, independently, be between about 1:1 and 50:1, or more (e.g., 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1; 12:1, 15:1, 20:1, 30:1, 40:1, 50:1, or more). Thus, in one example, the ratio of cardiomyocyte progenitors:endothelial cell progenitors:smooth muscle cell progenitors is 10:2:1.

5   During the injection, each cell type can be layered (laterally or vertically) such that the endothelial cell progenitors are close to endocardium, the vascular smooth muscle cells progenitors are in the middle, and cardiomyocyte progenitors close to epicardium. Alternatively, prior to the injection, the cell types can be mixed in a ratio of cell numbers, for example, 10:1:1 (cardiomyocyte

10   progenitors:endothelial cell progenitors:smooth muscle cell progenitors) and injected as a mixture into myocardium. For improved generation of blood vessels, certain angiogenic agents, e.g., VEGF (at, for example, 1-10 μM), can be mixed with the injected cells.

There are numerous methods known in the art to induce cells to become

15   cardiomyogenic. For example, the BMSCs can be cultured in culture medium that includes a cardiomyogenic cell-inducing amount of BMP-2 or bFGF. These methods may be employed in the practice of the invention.

Because mitotic cells will likely integrate into the myocardium more easily than will postmitotic cells, it is desirable that at least about 25%, 50%, 75%, 90%,

20   95% or more of the transplanted cells of step (c) be mitotic progenitor cells (e.g., cardiomyocyte progenitors, endothelial cell progenitors, or vascular smooth muscle cell progenitors).

In another aspect, the invention features a pharmaceutical composition that includes a population of stem cell-derived cells in a pharmaceutically acceptable

25   carrier or excipient, wherein at least about 10% and as many as 100% of the cells are endothelial cell progenitors.

In yet another aspect, the invention features a pharmaceutical composition that includes a population of stem cell-derived cells in a pharmaceutically acceptable carrier or excipient, wherein at least about 10% and as many as 100%

30   of the cells are vascular smooth muscle cell progenitors.

In another aspect, the invention also features a pharmaceutical composition that includes three types of cells: (1) cardiomyocytes or cardiomyocyte progenitors; (2) endothelial cells or endothelial cell progenitors; and (3) vascular smooth muscle cells or vascular smooth muscle cell progenitors in amounts

5   sufficient to improve cardiac function. Desirably, the cells are derived from stem cells (e.g., BMSCs). For improved generation of blood vessels, it is desirable that angiogenic agents also be included (e.g., 1-10 μM VEGF). Additionally, to facilitate the survival of the transplanted cells of invention, anti-apoptotic agents such as caspase inhibitors (e.g., zVADfmk) can be administered with the injected

10   cells.

The invention also features a method for producing cells for transplantation into a mammal (e.g., a human). The method includes the steps of (a) providing a population of BMSCs; (b) culturing the cells under conditions that induce the cells to adopt a cell type selected from the group consisting of a

15   vascular smooth muscle cell, an endothelial cell, an epicardial cell, an adipocyte, an osteoclast, an osteoblast, a macrophage, a neuronal progenitor, a neuron, an astrocyte, a skeletal muscle cell, a smooth muscle cell, a pancreatic precursor cell, a pancreatic β-cell, and a hepatocyte; (c) monitoring the state of differentiation of the cells of step (b); and (d) collecting the cells of step (b) when at least about

20   10% and as many as 100% of the cells are expressing detectable amounts of a protein that is specific for the induced cell type. Appropriate markers are described herein. The BMSCs can be, for example, human, pig, or baboon BMSCs. In one embodiment, the method includes the step of (e) transplanting the cells of step (d) into a mammal (e.g., a human). The transplantation can be an

25   autologous transplantation, i.e., the cells are transplanted into the mammal from which the bone marrow stem cells were derived. In another embodiment, the culturing and monitoring steps (b) and (c) are performed until at least about 15%, 20%, 30%, 40%, or 50% and as many as about 60%, 70%, 80%, 90%, 95%, or 99% of the cells expressing detectable amounts of the marker of the desired

30   lineage. Desirably, the culturing and monitoring steps (b) and (c) are performed

until at least about 50% and as many as 80% of the cells expressing detectable amounts of the marker of the desired lineage.

The invention also features a method for treating a disorder characterized by insufficient cardiac function in a mammal, desirably a human. The method

5   includes the steps of (a) isolating bone marrow stem cells from the mammal to be treated, (b) culturing the bone marrow stem cells under conditions that induce the cells to differentiate into cardiomyogenic cells, (c) monitoring the state of differentiation of the cells of step (b), (d) collecting the cells of step (b) when at least about 10% and as many as about 100% of the cells are cardiomyogenic

10   cells, and (e) transplanting the cardiomyogenic cells into the mammal.

The monitoring step (c) in all of the forgoing methods is desirably done by monitoring the differentiation of encapsulated BMSCs which have been transfected with a reporter gene construct. The BMSCs used for monitoring can be autologous, homologous, or heterologous to the BMSCs being cultured.

15   By "stem cell" is meant a cell capable of (i) self renewing, and (ii) producing multiple differentiated cell types, including one of the group selected from cardiomyocyte, endothelial cell, and vascular smooth muscle cell.

By "BMSC" is meant a bone marrow mesenchyme-derived stem cell that is CD45⁻. BMSCs are also referred to as "bone marrow stem cells" and "bone

20   marrow multipotent progenitor cells."

As used herein, by "nucleic acid" is meant either DNA or RNA. A "nucleic acid molecule" may be a single-stranded or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases. Unless otherwise specified, the left hand direction of the sequence of a single-stranded nucleic acid molecule is the 5'

25   end, and the left hand direction of double-stranded nucleic molecule is referred to as the 5' direction.

By "*Csx/Nkx2.5*" is meant a nucleic acid or polypeptide that is substantially identical to the mouse or human *Csx/Nkx2.5* cDNA or Csx/Nkx2.5 polypeptide and, when expressed in BMSCs, induces the cells to become

30   cardiomyogenic. Desirably, the nucleic acid shares at least 80% identity with mouse or human *Csx/Nkx2.5* over a stretch of 50 consecutive nucleotides, more

desirably at least 85%, and more desirably at least 90% or even 95% identity.

Gaps of up to 10% may be included in one or both of the sequences. Desirably,

the polypeptide shares at least 80% identity with mouse or human Csx/Nkx2.5

over a stretch of 25 consecutive amino acids, more desirably at least 85%, and

5   more desirably at least 90% or even 95% identity. Again, gaps of up to 10% may

be included in one or both of the sequences.

        By "treating" is meant reducing or alleviating at least one adverse effect or

symptom of a disorder characterized by insufficient cardiac function. Adverse

effects or symptoms of cardiac disorders are numerous and well-characterized.

10   Non-limiting examples of adverse effects or symptoms of cardiac disorders

include: dyspnea, chest pain, palpitations, dizziness, syncope, edema, cyanosis,

pallor, fatigue, and death. For additional examples of adverse effects or

symptoms of a wide variety of cardiac disorders, see Robbins, S. L. *et al.* (1984)

Pathological Basis of Disease (W. B. Saunders Company, Philadelphia) 547-609;

15   and Schroeder, S. A. *et al.* eds. (1992) Current Medical Diagnosis & Treatment

(Appleton & Lange, Connecticut) 257-356.

        By "disorder characterized by insufficient cardiac function" includes an

impairment or absence of a normal cardiac function or presence of an abnormal

cardiac function. Abnormal cardiac function can be the result of disease, injury,

20   and/or aging. As used herein, abnormal cardiac function includes morphological

and/or functional abnormality of a cardiomyocyte or a population of

cardiomyocytes. Non-limiting examples of morphological and functional

abnormalities include physical deterioration and/or death of cardiomyocytes,

abnormal growth patterns of cardiomyocytes, abnormalities in the physical

25   connection between cardiomyocytes, under- or over-production of a substance or

substances by cardiomyocytes, failure of cardiomyocytes to produce a substance

or substances which they normally produce, transmission of electrical impulses in

abnormal patterns or at abnormal times, and an altered chamber pressure resulting

from one of the aforementioned abnormalities. Abnormal cardiac function is seen

30   with many disorders including, for example, ischemic heart disease, e.g., angina

pectoris, myocardial infarction, chronic ischemic heart disease, hypertensive heart

disease, pulmonary heart disease (cor pulmonale), valvular heart disease, e.g., rheumatic fever, mitral valve prolapse, calcification of mitral annulus, carcinoid heart disease, infective endocarditis, congenital heart disease, myocardial disease, e.g., myocarditis, cardiomyopathy, cardiac disorders which result in congestive

5   heart failure, and tumors of the heart, e.g., primary sarcomas and secondary tumors.

"Administering," "introducing," and "transplanting" are used interchangeably and refer to the placement of the cardiomyogenic cells of the invention into a subject, e.g., a human subject, by a method or route which results

10   in localization of the cells at a desired site.

By "promoter" is meant a region of nucleic acid, upstream from a translational start codon, which is involved in recognition and binding of RNA polymerase and other proteins to initiate transcription. A "human promoter" is a promoter capable of initiating transcription in a human cell, and may or may not

15   be derived from a human cell. A "Csx/Nkx2.5 promoter" is one derived from the promoter region of a Csx/Nkx2.5 gene and that, when operably linked to a heterologous nucleic acid molecule, is capable of initiating transcription of that molecule (when present in a transcription medium capable of supporting transcription) in a cardiac cell.

20   By "enhancer element" or "enhancer" is meant a nucleic acid sequence that, when positioned proximate to a promoter and present in a transcription medium capable of supporting transcription, confers increased transcription activity relative to the transcription activity resulting from the promoter in the absence of the enhancer domain. A "Csx/Nkx2.5 enhancer" is one derived from

25   the promoter region of a Csx/Nkx2.5 gene and that, when operably linked to a heterologous nucleic acid molecule, is capable of initiating transcription of that molecule (when present in a transcription medium capable of supporting transcription) in a cardiac cell. A "Tie-2 enhancer" is one derived from the promoter region of a Tie-2 gene and that, when operably linked to a heterologous

30   nucleic acid molecule, is capable of initiating transcription of that molecule (when present in a transcription medium capable of supporting transcription) in

an endothelial cell. A "*Bves* enhancer" is one derived from the promoter region of a *Bves* gene and that, when operably linked to a heterologous nucleic acid molecule, is capable of initiating transcription of that molecule (when present in a transcription medium capable of supporting transcription) in a vascular smooth

5   muscle cell.

By "operably linked" is meant that two or more nucleic acid molecules (e.g., a nucleic acid molecule to be transcribed, a promoter, and an enhancer element) are connected in such a way as to permit transcription of the nucleic acid molecule in a suitable transcription medium.

10   By "derived from" is meant that a the nucleic acid molecule was either made or designed from a second nucleic acid molecule, the derivative retaining at least one important function of the nucleic acid molecule from which it was made or designed.

By "expression construct" is meant a nucleic acid molecule that supports

15   transcription. An expression construct of the present invention includes, at the least, a cardiac-specific enhancer element and a promoter. Additional elements, such as a transcription termination signal, may also be included, as described herein.

By "vector" or "expression vector" is meant an expression system, a

20   nucleic acid-based vehicle, a nucleic acid molecule adapted for nucleic acid delivery, or an autonomous self-replicating circular DNA (e.g., a plasmid). When a vector is maintained in a host cell, the vector can either be stably replicated by the cells during mitosis as an autonomous structure, incorporated within the genome of the host cell, or maintained in the host cell's nucleus or cytoplasm.

25   By "cardiac cell" is meant a differentiated cardiac cell (e.g., a cardiomyocyte) or a cell committed to producing or differentiating as a cardiac cell (e.g., a cardiomyoblast or a cardiomyogenic cell).

By "cardiomyocyte" is meant a muscle cell in heart that expresses detectable amounts of cardiac markers (e.g., alpha-myosin heavy chain, cTnI,

30   MLC2v, alpha-cardiac actin, and, *in vivo*, Cx43), contracts, and does not proliferate.

By "cardiomyoblast" is meant a cell that expresses detectable amounts cardiac markers, contracts, and proliferates.

By "cardiomyogenic cell" is meant a cell expressing detectable amounts of *Csx/Nkx2.5* RNA or protein, and does not show organized sarcomeric structures or contractions, and preferably does not express detectable amounts of myosin heavy chain protein.

By "epicardial cell" is meant a cell that expresses detectable amounts of Flk-1 and/or ICAM-2, and can become an endothelial cell.

By "endocardial cell" is meant a cardiac cell that expresses detectable amounts of Tie-2 and/or von Willebrand Factor.

By "endothelial cell" is meant a cell that expresses detectable amounts of at least one of the following RNAs or proteins: MUC18, VE-cadherin, N-cadherin, alpha- and beta-catenins, Flk-1, Tie-2, and CD34.

By "cells primed to differentiate as endothelial cells" is meant stem cells that have not been immortalized that were cultured under conditions that induce the cells to become endothelial cells, wherein at least about 10%, 25%, 50%, 75%, 90%, 95%, 99%, or even 100% of the cells are endothelial cells.

By "cells primed to differentiate as vascular smooth muscle cells" is meant stem cells that have not been immortalized that were cultured under conditions that induce the cells to become vascular smooth muscle cells, wherein at least about 10%, 25%, 50%, 75%, 90%, 95%, 99%, or even 100% of the cells are vascular smooth muscle cells.

By "specifically induce one cell type" when referring to differentiation of cultured BMSCs is meant a culture wherein at least 50% of BMSCs differentiate into the desired cell type (i.e., cardiomyocytes).

By "detectable amounts" of a protein is meant an amount of a protein that is detectable by immunocytochemistry using, for example, the methods provided herein. One method for determining whether a cell is detectably labeled with either CsX/Nkx2.5 or myosin heavy chain is provided below. Cultured cells are fixed with 4% formaldehyde for 20 minutes on ice, then incubated for 15 minutes in 0.2% Triton X-100 in phosphate-buffered saline (PBS). After three washes in

PBS, the cells are incubated in blotting solution (1% BSA and 0.2% Tween 20 in PBS) for 15 minutes. The samples are then treated with one of the following antibodies: anti-Csx (1:100-1:200, from S. Izumo, Harvard Medical School, Boston MA), MF-20 (1:50 to 200, from Developmental Studies Hybridoma Bank,

5   University of Iowa, Iowa City Iowa), anti-desmin (1:100-200, from Sigma-Aldrich, Inc., St. Louis MO), and, if desired, their isotype controls (for Csx, normal rabbit serum; for MF-20, mouse IgG2b; for desmin, mouse IgG1) at the same concentration, and incubated overnight at 4^0C in a moist chamber. The sample slides are then washed three times using a washing solution (0.5% Tween

10   20 in PBS) and incubated with secondary antibodies (for Csx, donkey anti-rabbit IgG, for MF-20 and anti-desmin, donkey anti-mouse IgG, all from Jackson ImmunoResearch Laboratories, Inc.) following the instructions provided by the vendors, followed by three washes. The samples are then examined under a fluorescence microscope (e.g., a Nikon TS100 microscope with a matching

15   fluorescence attachments) and visually scored for immunolabeling.

By "cardiac-specific enhancer element" is meant an element, operably linked to a promoter, that directs gene expression in a cardiac cell and does not direct gene expression in all tissues or all cell types. For example, certain cardiac-specific enhancer elements from *Csx/Nkx2.5* drive gene expression in

20   cardiac cells as well as in tongue and embryonic stomach. Cardiac-specific enhancers of the present invention may be naturally occurring or non-naturally occurring.

By "heterologous" is meant that the nucleic acid molecule originates from a foreign source or, if from the same source, is modified from its original form.

25   Thus, a "heterologous promoter" is a promoter not normally associated with the duplicated enhancer domain of the present invention. Similarly, a heterologous nucleic acid molecule is modified from its original form or is from a source different from the source from which the promoter to which it is operably linked was derived.

30

By "substantially pure nucleic acid" is meant nucleic acid that is free of the genes which, in the naturally-occurring genome of the organism from which the nucleic acid of the invention is derived, flank the nucleic acid. The term therefore includes, for example, a recombinant nucleic acid which is incorporated into a

5   vector; into an autonomously replicating plasmid or virus; or into the genomic nucleic acid of a prokaryote or a eukaryote cell; or which exists as a separate molecule (e.g., a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences. It also includes a recombinant nucleic acid that is part of a hybrid gene encoding

10   additional polypeptide sequence.

By "transgene" is meant any piece of a nucleic acid molecule (for example, DNA) that is inserted by artifice into a cell either transiently or permanently, and becomes part of the organism if integrated into the genome or maintained extrachromosomally. Such a transgene may include a gene that is

15   partly or entirely heterologous (i.e., foreign) to the transgenic organism, or may represent a gene homologous to an endogenous gene of the organism.

By "transgenic cell" is meant a cell containing a transgene. For example, a stem cell transformed with a vector containing an expression vector operably linked to a heterologous nucleic acid molecule can be used to produce a

20   population of cells having altered phenotypic characteristics. A cell derived from a transgenic organism is also a transgenic cell so long as the cells contains the transgene.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

25

Brief Description of Drawings

FIGURE 1 is a phase contrast micrograph of isolated, cultured bone marrow stem cells from mouse and dog.

FIGURE 2 is a series of micrographs showing murine BMSCs following a

30   14 day co-culture with chicken cardiomyocytes.

FIGURE 3 is a series of micrographs showing the staining and morphology of murine cardiomyocytes, undifferentiated BMSCs, and differentiated BMSCs using the MF-20 antibody, specific for sarcomeric myosin, or an anti-desmin antibody.

5   FIGURE 4 is a series of micrographs showing the morphology and *Csx/Nxk2.5* expression of canine BMSCs following in vitro differentiation.

FIGURE 5 is a series of micrographs demonstrating *in vitro* differentiation of murine BMSCs into cells of endothelial lineage.

FIGURE 6 is a series of micrographs showing the localization of

10   implanted BMSCs in infarcted dog myocardium 15 days after implantation.

FIGURE 7A is a series of micrographs showing the co-localization of implanted BMSCs, by DiI fluorescence, and cardiomyocytes, by anti-MHC α/β fluorescence, in the region in which the cells were injected.

FIGURE 7B is a micrograph showing increased survival of BMSCs

15   implanted with a caspase inhibitor, relative to untreated BMSCs.

FIGURE 8 is a series of micrographs showing the co-localization of implanted BMSCs, by DiI fluorescence, and cardiomyocytes, by anti-MHC α/β fluorescence in a region away from the site of injection.

FIGURE 9 is a series of micrographs showing the co-localization of

20   implanted BMSCs, by DiI fluorescence, and cardiomyocytes, by anti-MHC α/β fluorescence, in a region away from the site of injection.

FIGURE 10 is a series of micrographs showing the histopathology of the murine myocardial infarction 36 days after BMSC transplantation.

FIGURES 11-14 are micrographs showing the integration of BMSCs into

25   murine myocardial tissue, 36 days after transplantation.

FIGURE 15 is a pair of micrographs comparing β-galactosidase activity in hCsx-lacZ mouse BMSCs which are cultured in the absence (left panel) or presence (right panel) of growth factors which induce cardiomyogenic differentiation.

30

FIGURE 16A shows an exemplary encapsulated cell indicator system. In the illustration, the indicator cells 2 are encapsulated in an encapsulating material 4 such as alginate beads. The indicator cells 2 and encapsulating material 4 are contained in a permeable membrane or mesh 6 and co-cultured with cells 8 in a

5   culture vessel 10.

FIGURE 16B shows the use of encapsulating indicator cells to monitor myogenic differentiation in culture. Shown are micrographs of 11 μm and 30 μm nylon mesh, suitable for cell encapsulation; and micrographs showing the results of the β-galactosidase reaction performed using hCsx-lacZ mouse BMSC

10   indicator capsules containing varying cell numbers.

FIGURES 17-19 show echocardiograms of infarcted canine heart before (left panels) and after (right panels) induced BMSC transplantation.

FIGURE 20A is a schematic illustration of an exemplary three-barrel, one needle syringe. In this example, each barrel is injected simultaneously and evenly

15   into a reservoir adaptor that is connected to a single needle for a precise injection location. The three syringe barrels are connected at the top and are controlled by a single plunger depressor.

FIGURE 20B is a schematic illustration of a cross-section of the three-barrel, one needle syringe of FIGURE 20A.

20   FIGURE 21A is a schematic illustration of an exemplary three barrel, two needle syringe having one larger barrel for injection of one cell type. The two smaller barrels connect to a reservoir adaptor that is connected to one needle. The larger barrel has a separate needle for injection. It is desirable that the needle hole of the needle connected to the larger barrel is increased to maintain the

25   barrel/needle hole ratio of the smaller barrels, thereby maintaining equal injection pressure in all three barrels. While optional, the triangular arrangement of the three barrels allows close proximity of the two needles, while maintaining a parallel injection angle. The three syringe barrels are connected at the top and are controlled by a single plunger depressor for even injection pressure.

30

FIGURE 22A is a schematic illustration of a cross-section of the three-barrel, one needle syringe of FIGURE 21A.

FIGURE 22B is a schematic illustration of an exemplary three barrel, three needle design in which the each syringe barrel has its own needle for injection. If
5   desired, the triangular arrangement of the three barrels allows close proximity of the three needles while maintaining a parallel injection angle. The three syringe barrels are connected at the top and are controlled by a single plunger depressor for even injection pressure.

FIGURE 22C is a schematic illustration of a cross-section of the three-
10 barrel, one needle syringe of FIGURE 22A.

Detailed Description of the Invention

We have discovered that transplanting developmentally committed but undifferentiated cells will improve the survival, incorporation, and adaptation of
15 the implant in the target tissue.

In developing vertebrates, the early cardiac field is defined by the expression of the *Csx/Nkx2.5* gene. At this developmental stage, however, the *Csx/Nkx2.5*-expressing cells are still proliferating. We believe that the transplantation of *Csx/Nkx2.5*-expressing cells that are still proliferating will
20 result in an increased number of incorporated and functional cardiomyocytes in the heart.

We have also discovered a therapeutic cellular transplantation method in which blood vessels and myocardial tissue are collectively regenerated in the area of treated myocardium. This method includes the transplantation of
25 undifferentiated cells committed to become one of three cell types: cardiomyocytes, endothelial cells, or vascular smooth muscle cells.

It is desirable that there be an ample supply of the cells to be transplanted. Accordingly, in one aspect, the cells to be transplanted are derived from stem cells. One suitable stem cell is the BMSC, which can be isolated from adult bone
30 marrow. Once isolated, BMSCs can be treated with growth factors (referred to herein as "priming") to induce the cells toward a cardiomyocyte cell lineage, as is

described below. Alternatively, BMSCs can be primed toward an endothelial cell lineage, or a vascular smooth muscle cell lineage. In one embodiment, the BMSCs are monitored for lineage conversion using a cognate cell type-specific indicator system, such as the one described in U.S. Provisional Application Serial

5   No. 60/283,837, hereby incorporated by reference. To generate the cell type-specific indicator system, transgenic mouse lines are established using a gene construct that includes a cell lineage-specific enhancer/promoter-driven marker. For example, cardiomyocyte progenitor conversion can be monitored using encapsulated BMSCs from hCsx-LacZ transgenic mice. Once adequate marker

10   gene expression is detected in the cell population, the cells are collected and injected into the host myocardium.

In one embodiment, the cardiomyocyte progenitor cells, endothelial progenitor cells, and vascular smooth muscle cells are injected simultaneously into the host myocardium. For a proper distribution of each cell types in desired

15   areas, a multi-channeled syringe that is designed to inject multiple cell types can be used. The length of each of the needles and the distance between them can be adjusted according to the optimal locations of each cell types in the myocardium to be repaired.

Optimization of stem cells and stem cell derivative preparations is critical

20   for successful cell transplantation. To achieve maximum yield in cell transplantation, the implanted cells are desirably at the proper stage of commitment and differentiation. Currently, despite the known commitment and differentiation markers for many animal cells, it is difficult to determine the proper time to harvest cells during *in vitro* culture without performing time-

25   consuming molecular biological assays for the expression of these markers. We have discovered a biologically active indicator system with which to determine, in real time, the differentiation state of cells in culture. This indicator system is also useful, for example, for determining the amount of gene expression of proteins during cell growth or cell death.

30

Most tissue-specific gene expression is controlled by enhancer and repressor sequences at the transcriptional level. Generally, to confer tightly-regulated expression, enhancers adopt complex regulatory mechanisms that require the collaboration of multiple transcription factors. The binding sites

5   for these transcription factors may be many kilobases (kb) from the gene promoter and dispersed relative to each other.

When used to drive transgene expression in mice, cardiac enhancers from *hCsx/Nkx2.5* and *mCsx/Nkx2.5* recapitulate expression patterns of the endogenous *mCsx/Nkx2.5* (see, e.g., U.S. Patent Application Publication No. 2002022259,

10   hereby incorporated by reference). Among the mammalian cardiac enhancers known so far, one of these enhancers (the 7.5 kb enhancer) is the earliest enhancer that is active in all four heart chambers. Moreover, this enhancer displays no ectopic expression. Within this 7.5 kb fragment, two regions (referred to herein as homology domain A1 and homology domain A2 were

15   isolated that together, when operably linked to an hsp68 promoter-*lacZ* cassette, were capable of enhancing gene expression in a cardiac-specific manner. These two regions can also be used in the reporter constructs of the invention.

Example 1: Induction of cardiomyogenic cells from BMSCs

20   Marrow was isolated from adult mouse and dog. The BMSCs were isolated and cultured in medium containing 10% fetal bovine serum, 100 µM L-ascorbic acid-2-PO_4, 5-15 ng/ml leukemia inhibitory factor (LIF), and 20 nM dexamethasone (for mouse cultures, mouse LIF was used, while for dog cultures, human LIF was used). This *in vitro* condition allows the BMSCs to maintain

25   their self-renewing character and to expand by passaging without losing responsiveness to the differentiation agents such as growth factors. Further, stem cells cultured through multiple passages maintain a mesenchymal morphology and karyotye (Figure 1). After 14 days in culture with growth factors (50 ng/ml BMP2, 100 ng/ml bFGF), approximately 80% of the BMSCs were positively

30   stained with Csx/Nkx2.5, MF-20 (a monoclonal antibody specific for sarcomeric

myosin), and desmin antibodies, indicating that the cells had differentiated as cardiomyocytes (Figures 3 and 4).

To mimic the environment of the adult myocardium to which transplanted BMSCs are exposed, a co-culture model system was used. In this system,
5   BMSCs, labeled with a fluorescent tag for identification (Vybrant™), and primary chicken embryonic cardiomyocytes were co-cultured, at a ratio of 1:40, on glass slides coated with 5 ng/ml collagen. These mixed cultures were grown alone, in the presence of 25 ng/ml BMP2, or in the presence of 25 ng/ml bFGF. Cells were subsequently stained with anti-Csx/Nkx2.5, MF-20 (a monoclonal
10   antibody specific for sarcomeric myosin), and anti-desmin antibodies. Five days after the initiation, a few (0.1 – 1%) myosin-positive cells were detected in co-cultures grown in the presence of BMP2 or bFGF, while co-cultures grown in the absence of either growth factor were negative for all three antibodies. However, after two weeks of co-culture in the absence of growth factors, numerous BMSCs
15   were MF-20-positive, suggesting they had converted to a myogenic cell lineage (Figure 2). Thus, BMSCs can be induced to differentiate along a myogenic lineage using either growth factors such as BMP2 and bFGF, or by co-culture with differentiated cardiomyocytes.

In view of the foregoing results, we can regulate the rate and amount that
20   BMSCs become cardiomyogenic cells in culture by modulating the environment in which the cells are cultured. According to the transplantation method of the invention, it is desirable that at least 10% of the transplanted cells be cardiomyogenic cells (i.e., mitotic cells that express *Csx/Nkx2.5* but do not show organized sarcomeric structures or contractions, and preferably do not express
25   detectable amounts of myosin heavy chain RNA or protein). A higher percentage cardiomyogenic cells will result in increased incorporation of implanted cells. Thus, is it desirable that at least 10%, 25%, 50%, 75%, 85%, 90%, or 95% or more of the cells be cardiomyogenic cells. Real-time measurement of commitment can be performed using the cell indicator system described in
30   Example 5, below.

Example 2: BMSCs from humans and other mammals

         The foregoing example utilizes mouse BMSCs for illustrative purposes.

5   Human BMSCs are also known in the art to be capable of producing cardiac cells

(Pittenger *et al.*, Science 284: 143-147, 1999). BMSCs from other mammals

(e.g., humanized pig BMSCs) can also be used in the methods of the invention

(Levy *et al.*, Transplantation 69: 272-280, 2000).

10   **Example 3: Methods of inducing BMSCs to become cardiomyogenic**

         As is described above, co-culturing BMSCs with cardiomyocytes in the

presence of BMP2 and/or bFGF results in the induction of cardiomyogenic cells

capable of differentiating as cardiomyocytes in culture. The ratio of BMSCs to

inducer cells and the concentration of growth factor(s) can each be adjusted to

15   modulate the rate and amount of cardiomyogenic cell induction. For example, the

ratio of BMSCs to inducer cells can range from about 1:1 to about 1:1000 or

more. The concentration of BMP2 can range from about 0.5 ng/ml to about 1

µg/ml, while the concentration of bFGF can range from about 1 ng/ml to about 5

µg/ml. It is understood that other BMP/TGFβ and FGF family members can be

20   used instead of BMP2 and/or bFGF.

         Other methods known to induce BMSCs to become cardiomyogenic cells

can be used in the present invention. Not all methods that induce cardiomyocytes

can be used in the invention. For example, 5-azacytidine is used as the inducing

agent for cardiomyocytes (Makino *et al.*, J. Clin. Invest., 103: 697-705, 1999) but

25   is not appropriate in the methods of the invention. Since 5-azacytidine randomly

demethylates genomic sequences (thereby inducing normally silent genes),

treatment of the BMSCs with 5-azacytidine can generate a variety of cell types

(e.g., myocytes (MyoD positive), osteoblasts (osteocalcin positive), and

adipocytes (PPAR-γ positive)), in addition to cardiomyocytes (cardiac troponin I

30   positive) (Wakitani *et al.*, Muscle Nerve, 18: 1417-1426, 1995; Tomita *et al.*,

Circulation, 100 suppl II: 247-256, 1999). BMSCs exposed to 5-azacytidine are

known to rapidly upregulate *c-abl* and interleukin-6 transcripts while downregulating the expression of collagen I, a major matrix protein. (Andrews *et. al.*, Mol. Cell. Biol., 9: 2748-2751, 1989). In the methods of the invention, suitable factors or conditions are those that specifically induce one cell type (e.g.,
5   cardiomyocytes).

Example 4: Induction of other cell types

It may be desirable to induce cells types such as vascular smooth muscle cells and endothelial cells (or their precursors) for transplantation into the
10   myocardium because theses cells may generate new blood vessels around the transplanted cardiomyogenic cells. The cells can be transplanted alone, but preferably are transplanted with the appropriate cardiomyogenic cells, as described herein.

Differentiation of vascular smooth muscle cells can be determined using
15   the Bves gene enhancer (Reese *et al.*, Dev. Biol. 209: 159-171, 1999). Differentiation of endothelial cells can be determined using Tie-2 or von Willebrand Factor enhancers that have been cloned (Schnurch and Risau , Development 119: 957-968, 1993 and Coffin *et. al.*, Dev. Biol. 148: 51-62, 1991, respectively). Differentiation of embryonic epicardial cells (i.e., precursors of
20   endothelial cells) can be determined using Flk-1 or ICAM-2 enhancers (Shalaby *et al.*, Nature 376:62-66, 1995 and Tevosian *et al.*, Cell 101:729-739, 2000, respectively).

BMSCs were isolated as describe above and cultured in the presence of biological factors known to generate endothelial cell lineages during embryonic
25   development (2% FBS, 20 ng/ml VEGF, 1 ng/ml bFGF, and 2 ng/ml IGF-I). Flk-1, an endothelial-specific receptor tyrosine kinase, was robustly expressed in approximately 80% of cultured BMSCs, after 14 days in culture, indicating conversion to an endothelial cell lineage (Figure 5).

30

Example 5: Cell indicator system

As depicted in Figure 16A, the indicator system includes three components: indicator cells **2**, a cell encapsulation system (CES) **4**, and a permeable outside membrane or mesh **6** that helps retain the indicator cells in the

5   CES and separates the indicator cells **2** from those to be transplanted **8**.

In one example, the indicator system is useful in determining the state of cell commitment and differentiation of stem cells (e.g., BMSCs). As is described herein, it is desirable to prime human BMSCs such that about 5-100% (preferably about 80%) of the cells are cardiomyogenic cells (as determined by *Csx/Nkx2.5*

10   expression, the lack of organized sarcomeric structures or contractions, and preferably, the lack of myosin heavy chain RNA or protein). Thus, an extremely rapid assay is desired in order to minimize the time interval between harvesting the cells for the assay and transplantation. A rapid assay, therefore, ensures that the assay results are representative of the *Csx/Nkx2.5*-expressing cells which are

15   ultimately transplanted. The present invention provides such an assay. BMSCs from transgenic mice containing a *Csx* enhancer operably linked to a reporter gene are used as indicator cells. Suitable *Csx* enhancers are described, for example, in U.S. Patent Application Publication No. 2002022259, hereby incorporated by reference. The indicator cells are either encapsulated in a

20   biological material (e.g., alginate, collagen, gelatin, or chitosan) or attached onto a biodegradable polymer (e.g., non-porous microspheres of polylactic acid (PLA), polyglycolic acid (PGA), or polylactide/glycolide copolymer (PLGA)). The encapsulated or microsphere-attached cells are then surrounded by a membrane that permeable to oxygen, nutrients, and other biomolecules. Examples of

25   suitable membranes include porous transparent polyethylene terephthalate (PET) membrane, transparent nylon mesh, transparent porous nylon membrane, and porous transparent polytetrafluoroethylene (PTFE/Teflon).

In addition to retaining the indicator cells in the capsule, the outer membrane provides a physical integrity to the system. During the induction of

30   the human BMSCs into cardiomyogenic cells, the reporter gene operably linked to the *Csx* enhancer (e.g., a human *Csx* enhancer) will be expressed in the

indicator cells. Nontoxic detection of reporter gene expression indicates the differentiation state of the human cells. Suitable reporter genes include, without limitation, those encoding green fluorescent protein, β-galactosidase, and luciferase. After determining that the cells have reached the desired state of

5   differentiation, the entire indicator system (including the indicator cells, the encapsulating material, and permeable membrane) is removed. The cells to be implanted are then collected and prepared for transplantation. If desired, the cells can be frozen and stored until transplantation.

In the cell indicator system of the present invention, the indicator cells can

10   be any cell type in which the enhancer element/reporter gene construct is operable as the cells differentiate. In one example, BMSC cells transfected with the reporter construct are used. These cells can be any animal BMSCs or, alternatively, other cell types such as ES cells transfected with enhancer element/reporter gene construct, or BMSCs from an enhancer element/reporter

15   gene transgenic animals.

We demonstrate the principles described above, of an encapsulated cell indicator system, using murine BMSCs derived from hCsx-lacZ transgenic mice. We have found that BMSCs which are not induced to differentiate along a cardiomyogenic lineage stain weakly or not at all following a standard

20   β-galactosidase assay. (Figure 15). In contrast, BMSCs cultured according to the methods described above, which induce cardiomyogenic differentiation, produce a strongly positive signal (Figure 15). Accordingly, the murine hCsx-lacZ BMSCs are excellent candidates for encapsulation as a system that can be used to monitor the progression of myogenic differentiation (Figures 16A and 16B).

25   Such an indicator system provides several advantages over traditional techniques for assessing cell differentiation. Specifically, the capsules are easily recovered from the culture media and can be rapidly and reliably assayed. Further, because the capsule can be incorporated and recovered from every culture vessel, monitoring can be done on a plate-by-plate basis. It is not necessary to destroy an

30   entire culture for monitoring purposes, as is required using traditional histological techniques. This is particularly important when using BMSCs from a human

patient where bone marrow samples are difficult to obtain and few stem cells are available for culture and transplantation.

Murine hCsx-lacZ BMSCs can be encapsulated in any appropriate material whose properties are described above. Useful capsules can be made, for example, by embedding the cells in alginate and containing the alginate-embedded cells in 11 μm or 30 μm nylon mesh, available, for example, from Millipore Corp. (Bedford, MA), which is both durable and permeable to culture media and growth factors, oxygen, and chemical reagents used in the β-galactosidase assay. Using the methods described herein, capsules are desirably formed in solutions containing at least about 10^6 hCsx-lacZ BMSCs per milliliter; however the use of at least about 10^7 cells/ml is more desirable. Of course, as conditions vary, a person of ordinary skill could determine the appropriate concentration of indicator cells in the capsule system.

The specific indicator cells used to create the encapsulated monitoring system on this invention need not be murine cells. The indicator cells can be either heterologous or autologous to the transplant recipient. In cases where BMSCs are relatively plentiful, it is preferable to transfect a subset of the host BMSCs with a reporter construct, such as the one previously described. These autologous BMSCs are then encapsulated and used for monitoring purposes. Alternatively, in cases where BMSCs are in limited supply, non-autologous (homologous or heterologous) indicator BMSCs can be used.

Example 6: Methods for transplantation

The invention pertains to methods for treating disorders characterized by insufficient cardiac function in a subject by autologous or heterologous cardiac cell transplantation. The methods include administering to the subject the stem cell-derived cardiomyocyte progenitors, endothelial cell progenitors, and vascular smooth muscle progenitors of the invention, which are described in detail herein. Transplantation of the cells of the invention into the heart of the subject with a cardiac disorder results in replacement of lost or non-functioning ("hybernating") cardiomyocytes. The cells are introduced into a subject with a cardiac disorder in

an amount suitable to replace lost or non-functioning cardiomyocytes such that

there is an at least partial reduction or alleviation of at least one adverse effect or

symptom of the cardiac disorder. The cells can be administered to a subject by

any appropriate route that results in delivery of the cells to a desired location in

5   the subject where at least a portion of the cells remain viable. It is desirable that

at least about 5%, desirably at least about 10%, more desirably at least about

20%, yet more desirably at least about 30%, still more desirably at least about

40%, and most desirably at least about 50% or more of the cells remain viable

after administration into a subject. The period of viability of the cells after

10   administration to a subject can be as short as a few hours, e.g., twenty-four hours,

to a few days, to as long as a few weeks to months. One method that can be used

to deliver the cells of the invention to a subject is direct injection of the cells into

the ventricular myocardium of the subject (e.g., Soonpaa et al., Science 264:98-

101, 1994; Koh et al., Am. J. Physiol. 33:H1727-1733, 1993). The cells can be

15   administered in a physiologically compatible carrier, such as a buffered saline

solution. To treat disorders characterized by insufficient cardiac function in a

human subject, about $10^4 - 10^9$ cells are introduced into the human, e.g., into the

myocardium.

To accomplish these methods of administration, the cells of the invention

20   can be inserted into a delivery device that facilitates introduction by injection or

implantation of the cells into the subject. Such delivery devices include tubes,

e.g., catheters, for injecting cells and fluids into the body of a recipient subject.

In a preferred embodiment, the tubes additionally have a needle or needles

through which the cells of the invention can be introduced into the subject at a

25   desired location. It may be desirable to maintain each cell type in a different set

of conditions (such as in different media) during the injection. In such a case, a

multi-barrel syringe with one, two, or three needles can be used for injection

(Figures 20A, 20B, 21A, 21B, 22A, and 22B). If a three-barrel/two-needle

syringe is used, it is preferable that endothelial cell progenitors and smooth

30   muscle cell progenitors be mixed during the injection.

The cells of the invention can be inserted into such a delivery device in different forms. For example, the cells can be suspended in a solution or embedded in a support matrix when contained in such a delivery device. Preferably, the solution includes a pharmaceutically acceptable carrier or diluent

5   in which the cells of the invention remain viable. Pharmaceutically acceptable carriers and diluents include saline, aqueous buffer solutions, solvents and/or dispersion media. The use of such carriers and diluents is well known in the art. The solution is preferably sterile and fluid. Preferably, the solution is stable under the conditions of manufacture and storage and preserved against the

10   contaminating action of microorganisms such as bacteria and fungi through the use of, for example, parabens, chlorobutanol, phenol, ascorbic acid, or thimerosal. Solutions of the invention can be prepared by incorporating the cells as described herein in a pharmaceutically acceptable carrier or diluent and, as required, other ingredients.

15   Support matrices in which the cells of the invention can be incorporated or embedded include matrices which are recipient-compatible and which degrade into products that are not harmful to the recipient. Natural and/or synthetic biodegradable matrices are examples of such matrices. Natural biodegradable matrices include, for example, collagen matrices and alginate beads. Synthetic

20   biodegradable matrices include synthetic polymers such as polyanhydrides, polyorthoesters, and polylactic acid. These matrices provide support and protection for the cells *in vivo*.

Prior to introduction into a subject, the cells can be modified to inhibit immunological rejection. For example, to inhibit rejection of transplanted cells

25   and to achieve immunological non-responsiveness in a transplant recipient, the method of the invention can include alteration of immunogenic antigens on the surface of the cells prior to introduction into the subject. This step of altering one or more immunogenic antigens on the cells can be performed alone or in combination with administering to the subject an agent that inhibits T cell activity

30   in the subject. Alternatively, inhibition of rejection of the transplanted cells can be accomplished by administering to the subject an agent that inhibits T cell

activity in the subject in the absence of prior alteration of an immunogenic antigen on the surface of the transplanted cells. An agent that inhibits T cell activity is defined as an agent which results in removal (e.g., sequestration) or destruction of T cells within a subject or inhibits T cell functions within the

5   subject. T cells may still be present in the subject but are in a non-functional state, such that they are unable to proliferate or elicit or perform effector functions (e.g., cytokine production, cytotoxicity, etc). The agent that inhibits T cell activity may also inhibit the activity or maturation of immature T cells (e.g., thymocytes). A preferred agent for use in inhibiting T cell activity in a recipient

10   subject is an immunosuppressive drug that inhibits or interferes with normal immune function. A preferred immunosuppressive drug is cyclosporin A. Other immunosuppressive drugs that can be used include, for example, FK506 and RS-61443. In one embodiment, the immunosuppressive drug is administered in conjunction with at least one other therapeutic agent. Additional therapeutic

15   agents that can be administered include steroids (e.g., glucocorticoids such as prednisone, methyl prednisolone, and dexamethasone) and chemotherapeutic agents (e.g., azathioprine and cyclosphosphamide). In another embodiment, an immunosuppressive drug is administered in conjunction with both a steroid and a chemotherapeutic agent. Suitable immunosuppressive drugs are commercially

20   available.

In addition to its use in the treatment of cardiac-related disorders, cell transplantation therapy is applicable to a wide variety of diseases and disorders (e.g., Parkinson's disease, diabetes, spinal cord injury, multiple sclerosis). As with transplantation into the myocardium, the transplantation of mitotic cells that

25   are competent and primed to adopt the desired cell fate will likely aid in the integration of the transplanted cells, resulting in more of the desired cells incorporating and surviving in the host tissue. Enhancers useful for the detection of the differentiation, commitment, or competence of a cell lineage are depicted in Table 1, below.

30

Table 1

Cell Type	Marker	Reference
Vascular smooth muscle cell	Bves	Reese et al., Dev. Biol. 209:159-171, 1999.
Endothelial cell	Tie-2	Schnurch and Risau, Development 119:957-968, 1993.
	von Willebrand	Coffin et al., Dev Biol. 148:51-62, 1991.
Epicardial cell	Flk-1	Shalaby et al., Nature 376:62-66, 1995.
	ICAM-2	Tevosian et al., Cell 101:729-39, 2000.
Adipocyte	PPAR-g2	Zhu et al., PNAS 92:7921-7925, 1995.
Osteoclast	TRAP	Reddy, J. Bone Miner. Res. 10:601-606, 1995.
Osteoblast	Osteocalcin	Kesterson, Mol Endocrinol. 7:462-467, 1993.
Macrophage	CD11b	Dziennis et al., Blood. 85:319-329, 1995 .
Neuronal progenitor	Nestin	Yamaguchi et al., Neuroreport 11:1991-1996, 2000.
Neuron	Neurofilament	Leconte et al., J Mol Neurosci 5:273-295, 1994.
Astrocyte	GFAP	Nolte et al., Glia. 33:72-86, 2001.
Skeletal muscle cell	MyoD	Goldhammer et al., Science 256:538-42, 1992.
Smooth muscle cell	SMHC	Zilberman et al., Circ Res 1998 82:566-575, 1998.
Pancreatic precursor cell	Pdx-1	Marshak et al., Mol. Cell Biol. 20:7583-7590, 2000.
Pancreatic β-cell	Glucokinase	Jetton, et al., JBC. 269:3641-3654, 1993.
Hepatocyte	α-fetoprotein	Ghebranious, Dev 42:1-6, 1995.

Each of the foregoing references is hereby incorporated by reference.

Example 7: Canine model of myocardial infarction

BMSCs, which were directed toward a cardiogenic cell lineage *in vitro*, were transplanted into infarcted dog myocardial tissue. The dog myocardial infarction was created by permanent occlusion of the left coronary artery. The infarction was allowed to stabilize for at least two months prior to BMSC transplantation. In order to prevent immunorejection of the transplants, marrow was collected and BMSCs prepared from the individual transplant recipient dogs as follows. About four weeks after the ligation, after the myocardial infarction had been confirmed using echocardiogram, iliac bone was punctured to aspirate bone marrow. Bone marrow was immediately mixed with heparin, frozen and transported in dry ice to the tissue culture facility, where the bone marrow was thawed at 37°C, perturbated, washed once with regular DMEM, and plated in tissue culture flasks containing culture medium (10% fetal bovine serum, 100 µM L-ascorbic acid-2-PO$_4$, 5-15 ng/ml LIF, and 20 nM dexamethasone). At the time of harvest, BMSCs were labeled with DiI, a red fluorescent marker, to track the survival and progression of the cells following transplantation. The labeled BMSCs were then cultured in the presence of 100ng/ml bFGF for 4-7 days.

Cells (1.5-250 million) were harvested and injected into the infarcted region of the heart.

BMSC survival following transplantation was assessed by post-mortem visualization of DiI fluorescence. Large clusters of DiI-positive cells were

5   observed in the myocardium 15 days after transplantation, suggesting long-term viability of the BMSCs (Figure 6). Specifically, the DiI-labeled stem cells were observed within regions of the myocardium containing MF-20-positive cardiomyocytes and in the infarcted regions which were devoid of MF-20-positive cardiomyocytes (Figure 6). Further, the border region of the infarcted

10   area contained DiI positive stem cells which also express the cardiac muscle-specific marker MHC α/β (Figures 7-9). Together, these data demonstrate that transplanted BMSCs, which have been conditioned *in vitro* according to the described methods, survive and incorporate into the host myocardium and express markers characteristic of cardiac differentiation.

15

Example 8: BMSC implantation reduces infarction size

The canine myocardial infarction model described in Example 7 was used for *in vivo* assessment, by echocardiogram (ECG), of the restorative effects of BMSC transplantation. ECGs were performed 3.5, 4.5, and 5 weeks after BMSC

20   transplantation (Figures 19, 17, and 18, respectively) and compared to pre-implantation ECGs. In each animal, contraction of the infarct area became more synchronized with neighboring area of the myocardium. Thus, the ECG results confirm the histological findings of Example 7 and demonstrate that transplantation of stimulated, cultured BMSCs results in a partial restoration of

25   cardiac tissue following infarction.

Example 9: Murine model of myocardial infarction

The long-term viability of implanted BMSCs was also investigated using a murine cardiac infarction model system. In order to prevent immunorejection,

30   BMSCs were isolated from marrow collected from mice isogenic to those used for transplantation. As described above, the BMSCs were cultured in the

presence of 100 ng/ml bFGF for 4-7 days, then fluorescently labeled with DiI and harvested. Infarctions were created by left coronary artery banding. The treated BMSCs were then injected into the infarction area as follows. BMSCs (100,000 to 500,000 in 10 µl PBS or HBSS) were injected in the anteroseptal LV

5   myocardium in an oblique way, using a 50 microliter Hamilton syringe with a matching 29G or 30G Hamilton needle. During the surgery, the mouse was kept on a custom made heated bed maintained at 37 °C using a feedback temperature controller, and respiration was assisted using a mouse respirator (set volume 200 microliters, 110/min rate). Thirty-six days after transplantation, the infarcted area

10   was analyzed for the presence of DiI-labeled cells and cardiomyocyte viability. As observed in the canine model, labeled BMSCs were incorporated within the murine myocardial infarct. Further, DiI-labeled cells present in the myocardium exhibited morphologies characteristic of cardiomyocytes. Hematoxylin and eosin staining of this region shows striations, corkscrew nuclei, and elongated fibers

15   that are characteristic of cardiac muscle (Figure 10) inside of the infarct. We also observed DiI-positive cells adjacent to the infracted area of the myocardium. Visualization of cardiomyocytes using α-MHC, MF-20, and cardiac troponin antibody staining demonstrated that the DiI-labeled cells (transplanted BMSCs) were located completely within the cardiac myofibrils (Figures 11, 12, and 14).

20   Transplanted BMSCs were also incorporated in the neighboring regions of the myocardium (Figure 13). Thus, the transplanted stimulated BMSCs fully integrated into both the normal and infarcted cardiac tissue and continued differentiating into cardiomyocytes; a process begun prior to transplantation, during the *in vitro* stimulation.

25

Example 10: Methods of inducing stem cells to become endothelial progenitor cells

To generate primed endothelial progenitor cells, isolated stem cells (*e.g.*, human BMSCs) are primed using VEGF (10ng/ml), bFGF (1ng/ml), and IGF-I

30   (2ng/ml) for a period of 4-7 days (Shi et al., Blood 92:362-367, 1998). As a conversion indicator in the cell indicator system, stem cells containing a Tie

enhancer operably linked to a reporter gene can be used (Schlaeger et al., Proc. Natl. Acad. Sci. USA 94:3058-3063, 1997).

Example 11: Methods of inducing stem cells to become vascular smooth muscle progenitor cells

To generate primed vascular smooth muscle progenitor cells, isolated stem cells (*e.g.*, human BMSCs) can be primed using PDGF (1-10 ng/ml) and TGF-β (1-10 ng-ml) for a period of 4-7 days (Hirschi et al., J. Cell Biol. 141:805-814, 2000). As a conversion indicator in the cell indicator system, stem cells containing a Bves enhancer operably linked to a reporter gene can be used (Reese et al, Dev. Biol. 209:159-171,1999).

Other Embodiments

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

We claim:

Claims

1. A method for producing cells for transplantation into myocardial tissue of a mammal comprising the steps:

    (a)   providing bone marrow stem cells that have not been immortalized,

    (b)   culturing said bone marrow stem cells under conditions that induce said cells to differentiate into cardiomyogenic cells,

    (c)   monitoring the differentiation state of the cells of step (b), and

    (d)   collecting the cells of step (b) when at least about 10% and as many as 100% of said cells are cardiomyogenic cells.

2. The method of claim 1, further comprising the step:

    (e)   transplanting said cardiomyogenic cells into said mammal.

3. The method of claim 2, wherein said bone marrow stem cells are derived from said mammal.

4. The method of claim 1, wherein said mammal is a human.

5. The method of claim 1, wherein said collecting step (d) is performed when at least about 50% and as many as 80% of said cells of step (b) are cardiomyogenic cells.

6. The method of claim 1, wherein said culturing step (b) comprises culture conditions where the culture medium contains at least one of BMP-2 and bFGF in a quantity sufficient to induce said cells to differentiate into cardiomyogenic cells.

7. The method of claim 1, wherein said monitoring step (c) comprises determining the differentiation state of autologous bone marrow stem cells that are co-cultured with said bone marrow stem cells of step (b), wherein the differentiation state of said autologous bone marrow stem cells correlates with the

5   differentiation state of said bone marrow stem cells of step (b).

8. The method of claim 1, wherein said monitoring step (c) comprises assessing differentiation of homologous or heterologous bone marrow stem cells that are co-cultured with said bone marrow stem cells of step (b), wherein the

10   differentiation state of said homologous or heterologous bone marrow stem cells correlates with the differentiation state of said bone marrow stem cells of step (b).

9. A method for producing cells for transplantation into a mammal comprising the steps:

15   (a)   providing bone marrow stem cells that have not been
                      immortalized,

                (b)   culturing said bone marrow stem cells under conditions that
                      induce said cells to differentiate into vascular smooth muscle
                      cells, endothelial cells, epicardial cells, adipocytes, osteoclasts,

20   osteoblasts, cardiac fibroblasts, macrophages, neuronal
                      progenitors, neurons, astrocytes, skeletal muscle cells, smooth
                      muscle cells, pancreatic precursor cells, pancreatic β-cells, or
                      hepatocytes,

                (c)   monitoring the differentiation state of cells of step (b), and

25   (d)   collecting the cells of step (b) when at least about 10% and as
                      many as 100% of said cells express detectable amounts of a
                      protein specific for said cell type.

10. The method of claim 9, further comprising the step:

(e)   transplanting said cells from step (d) into said mammal.

11. The method of claim 9, wherein said bone marrow stem cells are

5   derived from said mammal.

12. The method of claim 9, wherein said mammal is a human.

13. The method of claim 9, wherein said collecting step (d) is performed

10   when at least about 50% and as many as 80% of said cells of step (b) are

differentiated into said cell type.

14. The method of claim 9, wherein said monitoring step (c) comprises

assessing differentiation of autologous bone marrow stem cells that are co-

15   cultured with said bone marrow stem cells of step (b), wherein the differentiation

state of said autologous bone marrow stem cells correlates with the differentiation

state of said bone marrow stem cells of step (b).

15. The method of claim 9, wherein said monitoring step (c) comprises

20   assessing differentiation of homologous or heterologous bone marrow stem cells

that are co-cultured with said bone marrow stem cells of step (b), wherein the

differentiation state of said homologous or heterologous bone marrow stem cells

correlates with the differentiation state of said bone marrow stem cells of step (b).

25

16. A method for treating a disorder characterized by insufficient cardiac function in a mammal, said method comprising the steps:

(a) isolating bone marrow stem cells from said mammal,

(b) culturing said bone marrow stem cells under conditions that induce said cells to differentiate into cardiomyogenic cells,

(c) monitoring the state of differentiation of cells of step (b),

(d) collecting the cells of step (b) when at least about 10% and as many as 100% of said cells are cardiomyogenic cells, and

(e) transplanting said cardiomyogenic cells into said mammal.

17. The method of claim 16, wherein said mammal is a human.

18. The method of claim 16, wherein said collecting step (d) is performed when at least about 50% and as many as 80% of said cells of step (b) are differentiated into said cell type.

19. The method of claim 16, wherein said monitoring step (c) comprises assessing differentiation of autologous bone marrow stem cells.

20. The method of claim 16, wherein said monitoring step (c) comprises assessing differentiation of homologous or heterologous bone marrow stem cells.

21. A method for producing cells primed to differentiate as endothelial cells upon transplantation into a mammal, said method comprising the steps of:

(a) providing a population of stem cells that have not been immortalized;

(b) culturing said cells of step (a) under conditions that induce said cells to differentiate as endothelial progenitor cells; and

(c) collecting the cells of step (b) when at least about 10% and as many as 100% of the cells are endothelial progenitor cells, wherein said cells are primed to differentiate as endothelial cells upon transplantation into a mammal.

22. The method of claim 21, further comprising, between steps (b) and (c), the step of monitoring the state of differentiation of cells of step (b).

23. A method for producing cells primed to differentiate as vascular
5 smooth muscle cells upon transplantation into a mammal, said method comprising the steps of:

(a) providing a population of stem cells that have not been immortalized;

(b) culturing said cells of step (a) under conditions that induce said cells to differentiate as vascular smooth muscle progenitor cells; and

10 (c) collecting the cells of step (b) when at least about 10% and as many as 100% of the cells are vascular smooth muscle progenitor cells, wherein said cells are primed to differentiate as vascular smooth muscle cells upon transplantation into a mammal.

15 24. The method of claim 23, further comprising, between steps (b) and (c), the step of monitoring the state of differentiation of cells of step (b).

25. A method for treating a mammal diagnosed as having a disorder characterized by insufficient cardiac function, said method comprising
20 introducing to the myocardial tissue of said mammal:

(a) cardiomyocytes or cardiomyocyte progenitor cells;

(b) endothelial cells or endothelial cell progenitors; and

(c) vascular smooth muscle cells or vascular smooth muscle cell progenitors, wherein said cells are introduced in amounts sufficient to improve
25 cardiac function.

26. The method of claim 25, wherein at least one million cardiomyocyte progenitor cells are injected into said myocardium with the other two cell types in a ratio of about 10:1:1 cardiomyocyte progenitors:endothelial cell
30 progenitors:vascular smooth muscle cell progenitors.

27. The method of claim 25, further comprising introducing to said myocardium a caspase inhibitor.

28. The method of claim 25, wherein said mammal is a human.

5

29. A pharmaceutical composition comprising:

(a) cardiomyocytes or cardiomyocyte progenitors;

(b) endothelial cells or endothelial cell progenitors; and

(c) vascular smooth muscle cells or vascular smooth muscle cell

10   progenitors, wherein said cells are in amounts sufficient to improve cardiac function upon introduction to a human.

Isolation and Culture of Bone Marrow Stem Cells

Passage 18   Passage 1   Passage 13   Passage 1

Dog   Mouse

Figure 1

Figure 2

BMSCs cultured with cardiac myocytes and
induction factors express a muscle-specific protein

Mouse BMSCs   MF-20   Merged Image

Mouse BMSCs   MF-20   Phase

Figure 3

Comparison of (Cardiac) Myocyte Marker Expression
Between Primary Cardiomyocytes and Undifferentiated
Mouse BMSCs

Figure 4

In vitro Dog BMSCs Differentiation

Csx Immunostaining

Phase

Figure 5

Expression of an Endothelial Cell Marker in In Vitro
Differentiated Mouse BMSCs

anti-flk-1

Merged
Image

DAPI

Phase

Figure 6

Detection of the Implanted BMSCs in the Infarct Area of a Dog Heart (15 Days Post-implantation)

MF-20

Merged Image

Arrows indicate position of DiI labeled cells.

DiI

DAPI

Phase

Figure 7A

Detection of the Implanted BMSCs in the Infarct Area
of a Dog Heart (15 Days Post-implantation)

Figure 7B

with zVADfmk

without zVADfmk

Figure 8

Detection of the Implanted BMSCs in the Infarct Area
of a Dog Heart (15 Days Post-implantation)

anti-
MHC α/β

Merged
Image

DiI

DAPI

Figure 8d

Figure 9

Detection of the Implanted BMSCs in the Infarct Area
of a Dog Heart (15 Days Post-implantation)

anti-
MHC α/β

Merged
Image

DiI

DAPI

Phase

Figure 9d

Figure 10

Incorporation of injected cells into myocardium of infarcted mouse heart (36 days after injection with treatments)

Figure 11

Incorporation of injected cells into myocardium of infarcted
mouse heart (36 days after injection with treatments)

DiI   αMHC   Merge

DAPI   Phase   Phase/DAPI/DiI

Figure 12

Incorporation of injected cells into myocardium of infarcted mouse heart (36 days after injection with treatments)

Figure 13

Incorporation of injected cells into myocardium of infarcted mouse heart (36 days after injection with treatments)

Figure 14

Incorporation of injected cells into myocardium of infarcted mouse heart (36 days after injection with treatments)

Troponin

DiI

Phase

Merge

Differentiation of the BMSCs from hCsx-lacZ Mouse
(to be used in the Cell Differentiation Indicator System)

Autodifferentiation   Induced Differentition

Figure 15

Figure 16

Design of the Cell Differentiation Indicators
Using LacZ Positive Cells

11 μm

30 μm
nylon

1x10⁴   0.8x10⁶   1x10⁷

lacZ-positive cells/ml

Figure 17

Echocardiogram of an Infarcted Dog Heart

Baseline (#3328)

4.5 Weeks after Cell Injection

Figure 18

Echocardiogram of an Infarcted Dog Heart


Baseline (#3337)

5 Weeks after Cell Injection

Figure 19

Echocardiogram of an Infarcted Dog Heart

Baseline (#3338)   3.5 Weeks after Cell Injection

Fig. 20A

Fig. 20B

Fig. 21B

Fig. 21A

Fig. 22A

Fig. 22B